Spacelabs Healthcare has closed its acquisition of Del Mar Reynolds Medical, the cardiac division of UK group Ferraris. Hawthorne, California-based Spacelabs had agreed in July to acquire the business for £14m ($25.5m) in cash (see Clinica No 1213, p 15). The acquisition will provide Spacelabs' with a broader presence in the UK and German cardiac monitoring markets, as well as double the size of its existing core lab business.
Spacelabs completes Del Mar Reynolds Medical acquisition:
Spacelabs Healthcare has closed its acquisition of Del Mar Reynolds Medical, the cardiac division of UK group Ferraris. Hawthorne, California-based Spacelabs had agreed in July to acquire the business for £14m ($25.5m) in cash (see Clinica No 1213, p 15). The acquisition will provide Spacelabs' with a broader presence in the UK and German cardiac monitoring markets, as well as double the size of its existing core lab business.
More from Archive
More from Medtech Insight
Existing legislation already offers a route, albeit rarely used, for orphan and innovative devices to reach the market more quickly. It should be used more; manufacturers and notified bodies do not need to wait for official changes to the EU’s medtech regulations.
President Trump’s CDC director nominee was pulled after vaccine positions appeared too extreme for some Republicans, but the nominations to lead the FDA and NIH advanced to the Senate floor despite last-minute drama.
Insight into the knock-on effects on innovation adoption and procurement is keenly awaited by medtechs.